The Sarcoma Center at Dana-Farber Cancer Institute — one of the largest and most respected sarcoma programs in the world — is leading critical efforts toward understanding the specific genetic changes that cause sarcomas. New findings inform the design of innovative diagnostic techniques and treatments. Our recent investigations — of unprecedented depth and scope — aim to increase treatment efficacy through research into resistance mechanisms and novel therapeutics.
We provide care and do research for a broad range of soft tissue and bone sarcomas, including, but not limited to:
- Alveolar Soft Part Sarcoma (ASPS)
- Angiosarcomas
- Ewing's Sarcoma
- Gastrointestinal Stromal Tumors (GIST)
- Leiomyosarcomas
- Liposarcoma
- Malignant Peripheral Nerve Sheath Tumors (MPNST)
- Osteosarcoma
- Pigmented Villonodular Synovitis (PVNS)/Tenosynovial Giant Cell Tumor (TGCT)
- Sarcoma of Soft Tissue (STS)
Patients who are interested in participating in a clinical trial at Dana-Farber are invited to visit our Find a Clinical Trial page and filter by "sarcoma" or other conditions.